strategies to minimize the occurrence of crs and icans in patients treated with car-t therapy
Published 1 year ago • 218 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:23
management of crs and icans after car-t therapy for all
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
2:09
treating crs and icans: current approaches and future outlooks
-
1:46
real-world experiences with toxicity in patients treated with car-t cell therapy
-
3:43
car t-cell toxicity: crs, icans and prolonged cytopenias
-
3:57
mechanisms and management of short- and long-term car-t toxicities
-
6:07
managing crs in car t-cell therapy
-
3:49
strategies to improve cost & access to car-t therapy
-
2:57
strategies to optimize car-t therapy in myeloma: bringing car-t into earlier lines
-
1:09
optimizing car-t outcomes in dlbcl: possible combination strategies & sequencing of agents
-
3:59
strategies to improve car t-cell manufacturing
-
1:59
nursing perspectives: a look at icans in car-t
-
4:44
optimizing lymphodepletion chemotherapy in car-t therapy recipients
-
3:19
car-t and neurotoxicity: frequency and management
-
1:49
car-t cell approaches in cll: current progress & future directions
-
1:07
optimizing car-t therapy: regulating car t-cells in vivo
-
4:06
a phase ii trial of intermittent treatment strategies for ndmm to avoid asct
-
1:39
the role of myeloid cells in car-t cell therapy
-
4:16
the challenges with car t-cell therapy for t-all and the progress made to overcome these challenges